Oral Contraceptives May Be Cause of Drop in Ovarian CA Mortality

This article originally appeared here.
Share this content:
Oral Contraceptives May Be Cause of Drop in Ovarian CA Mortality
Oral Contraceptives May Be Cause of Drop in Ovarian CA Mortality

WEDNESDAY, Sept. 7, 2016 (HealthDay News) -- Ovarian cancer mortality is down dramatically in many parts of the world, and the use of oral contraceptives (OCs) may be a main reason why, according to a study published online Sept. 5 in the Annals of Oncology.

The analysis of World Health Organization data found that the ovarian cancer mortality rate declined 16 percent in the United States and almost 8 percent in Canada between 2002 and 2012.

In the European Union, the ovarian cancer mortality rate declined 10 percent, though some countries saw far more significant decreases. The United Kingdom's ovarian cancer mortality rate declined by 22 percent. Denmark and Sweden each saw a reduction of 24 percent in their mortality rate from ovarian cancer. Ovarian cancer deaths also decreased about 12 percent in both Australia and New Zealand. In Latin America, the results were mixed. Argentina, Chile, and Uruguay had decreases in ovarian cancer mortality rates between 2002 and 2012. Brazil, Colombia, Cuba, Mexico, and Venezuela all had increases.

"The main reason for the favorable trends is the use of OCs, particularly, in the United States and countries of the European Union where OCs were introduced earlier," the authors write. "Declines in menopausal hormone use may also have played a favorable role in elderly women, as well as improved diagnosis, management, and treatment."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »